Eribulin mesylate exerts antitumor effects via CD103.

ABSTRACT: Eribulin mesylate (ERB) is a synthetic analog of halichondrin B, inhibiting tumor cell growth by disrupting microtubule function. Recently, anticancer drugs have been shown to not only act directly on tumor cells but also to exert antitumor effects by modifying the tumor environment. Although ERB has also been speculated to modify the tumor microenvironment including the immune response to tumors, the precise mechanism remains unclear. In our study, ERB suppressed the tumor growth of MC38 colon cancer in wildtype mice, whereas ERB failed to inhibit the tumor growth in Rag1-deficient mice which lack both B and T cells. Moreover, depletion of either CD4⁺ or CD8⁺ T cells abrogated the antitumor effect of ERB, indicating that both CD4⁺ and CD8⁺ T cel

SUBMITTER: Oya K 

PROVIDER: S-EPMC10228394 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature